Results 71 to 80 of about 8,864 (209)
EJNMMI Research, 2023 Background The accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression.
Ulrika Jahn +4 more
doaj +1 more source
Journal of Applied Clinical Medical Physics, Volume 27, Issue 6, June 2026.Abstract Background The rapid evolution of deep learning (DL), particularly the emergence of generative adversarial networks (GANs) has demonstrated strong potential for generating high‐resolution, voxel‐level dosimetric data. However, GAN‐based approaches have not yet been broadly applied to the generation of tissue‐specific dose voxel kernels (DVKs ...
Otieno Erick Kapis +3 more
wiley +1 more source
Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2015 Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy.
Alireza Aslani +6 more
doaj
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, Volume 13, Issue 35, 24 June 2026.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Advanced Molecular Imaging Probes for Skeletal Diseases: Current Progress and Future Perspectives
iRADIOLOGY, Volume 4, Issue 3, Page 206-218, June 2026.This review summarizes the potential molecular imaging techniques and probes for common orthopedic diseases, such as trauma, infection, metabolism, tumor, joint, spine and other fields, aiming to provide a basis for the development of a new generation of molecular imaging probes.
Shuo Guo +6 more
wiley +1 more source
, 2019 Malignant insulinoma is an extremely uncommon tumor that is usually accompanied by severe hypoglycemia that is difficult to manage. At this time, the long-term effect of 177Lu-DOTATATE (lutetium [Lu-177]-DOTA-Tyr3-octreotate) on this tumor is not well ...
Navarro, Teresa +5 more
core +1 more source
Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment
Journal of Neuroendocrinology, Volume 38, Issue 6, June 2026.Abstract Neuroendocrine tumours (NETs) are well‐differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes.
Victoria Jacquot +4 more
wiley +1 more source
BMC CancerBackground Peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE is an established treatment for somatostatin receptor–expressing neuroendocrine tumors.
Johan K.E. Spetz +6 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Paragangliomas may appear biochemically silent, yet still behave as functional tumors with severe intraoperative consequences. Normal preoperative catecholamine screening does not exclude the risk of hypertensive crisis during surgery.
Abdul Basit +5 more
wiley +1 more source
Development of a hybrid image-based method for bone marrow dosimetry during 177Lu-DOTATATE treatment [PDF]
Radionuclide therapy with 177Lu-DOTATATE is a well-established treatment for patients with advanced neuroendocrine tumors overexpressing somatostatin receptors.
Hagmarker, Linn
core +1 more source